RxSight Inc
$14.5M 7,552 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. reported $14,521,670.06 across General Payments, Research, and Ownership to 186,436 physicians and teaching hospitals across 186,436 transactions.
- $14.5M
- All-tracks total
- 186,436
- Transactions
- 186,436
- Recipients
- +$667.7K
- General Payments vs PY2023
Otsuka America Pharmaceutical, Inc. reported $14,521,670.06 across all CMS Open Payments tracks (General + Research + Ownership) to 186,436 physicians and teaching hospitals in Program Year 2024 - ranking #129 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $14,521,670.06, averaging $77.89 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer otsuka-america-pharmaceutical-inc Otsuka America Pharmaceutical, Inc.
$14.5M · #129/1,925 · 0.1% industry · PY2024
- TOT $14.5M
- RANK #129
- SHARE 0.1%
- TXN 186,436
- RCP 186,436
- CAT 8
- GEN $14.5M
- ΔGEN +$667.7K
- TOP1 1.8%
- PY 2024
Volume peers
Nearest volume peer: RxSight Inc ($14.5M)
Otsuka America Pharmaceutical, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Otsuka America Pharmaceutical, Inc.'s CMS-reported General Payments increased by $667.7K (+4.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OTSUKA AMERICA PHARMACEUTICAL, INC.PY2023: OTSUKA AMERICA PHARMACEUTICAL, INC.PY2024: Otsuka America Pharmaceutical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $13,853,960.85
- PY2024
- $14,521,670.06
What the Data Shows for Otsuka America Pharmaceutical, Inc.
$14,521,670.06: that is what Otsuka America Pharmaceutical, Inc. reported in payments to 186,436 physicians and teaching hospitals during Program Year 2024, spread across 186,436 transactions ($77.89 per transaction, $77.89 per recipient). The company sits at rank #129 of 1,925, representing 0.1% of all industry payments reported nationwide for the year.
"Compensation for Services Other Than Consulting" leads the 8-category general-payment breakdown below at $8.0M (55.1% of General Payments, 3,595 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 8 types of general payments, Otsuka America Pharmaceutical, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $8.0M - 55.1% of General Payments.
Otsuka America Pharmaceutical, Inc. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (55.1%), Food and Beverage (30.4%), and Travel and Lodging (8.1%). The remaining 5 categories make up 6.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Otsuka America Pharmaceutical, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Otsuka America Pharmaceutical, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $8.0M | 3,595 | 55.1% |
| Food and Beverage | $4.4M | 176,914 | 30.4% |
| Travel and Lodging | $1.2M | 5,557 | 8.1% |
| Consulting Fee | $620.2K | 181 | 4.3% |
| Grant | $267.1K | 2 | 1.8% |
| Space Rental or Facility Fees | $30.2K | 18 | 0.2% |
| Charitable Contribution | $3.2K | 14 | 0.0% |
| Education | $1.1K | 155 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $913,719.66 (6.3%) of $14,521,670.06 in this company's General Payments records across 54,674 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Otsuka America Pharmaceutical, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Langley Porter Psychiatric Hospital
$266,050.75 across 2 reported transactions
- 2
Rebecca Roma
$172,512.46 across 253 reported transactions
- 3
Charles Nguyen
$171,302.83 across 252 reported transactions
- 4
Leslie Citrome
$152,997.30 across 192 reported transactions
- 5
Amita Rajesh Patel
$150,856.32 across 154 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Otsuka America Pharmaceutical, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Otsuka America Pharmaceutical, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Otsuka America Pharmaceutical, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
NovApproach Spine, LLC
$14.5M 178 recipients
Compare payment profiles
Swedish Orphan Biovitrum Ab
$14.7M 55 recipients
Compare payment profiles
Otsuka Pharmaceutical Development & Commercialization, Inc.
$14.8M 4,515 recipients
Compare payment profiles
Roche Diagnostics Operations, Inc.
$14.9M 0 recipients
Compare payment profiles
Argenx US, Inc.
$14.1M 19,529 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.